CDC Model Performance Evaluation Program (MPEP) for Mycobacterium tuberculosis
Drug Susceptibility Testing
Attachment 7
MPEP M. tuberculosis Results Worksheet
MPEP Mycobacterium tuberculosis Results Worksheet
Enter your drug susceptibility test results for each isolate by using the data worksheets below. There are two worksheets—one for growth-based drug susceptibility results and one for molecular test results. These worksheets are provided as a tool for recording results prior to online data entry.
Growth-based Drug Susceptibility Worksheet: Isolate Method
Drug |
Resistant |
Susceptible |
Intermediate |
Contaminated/ No Growth |
No Interpretation |
Not Done |
Rifampin |
|
|
|
|
|
|
Isoniazid—low |
|
|
|
|
|
|
Isoniazid—high |
|
|
|
|
|
|
Ethambutol |
|
|
|
|
|
|
Pyrazinamide |
|
|
|
|
|
|
|
|
|
|
|
|
|
Streptomycin |
|
|
|
|
|
|
Ofloxacin |
|
|
|
|
|
|
Ciprofloxacin |
|
|
|
|
|
|
Moxifloxacin |
|
|
|
|
|
|
Levofloxacin |
|
|
|
|
|
|
Amikacin |
|
|
|
|
|
|
Kanamycin |
|
|
|
|
|
|
Capreomycin |
|
|
|
|
|
|
Ethionamide |
|
|
|
|
|
|
Rifabutin |
|
|
|
|
|
|
Cycloserine |
|
|
|
|
|
|
Para-aminosalicylic Acid |
|
|
|
|
|
|
Rifapentine |
|
|
|
|
|
|
Bedaquiline |
|
|
|
|
|
|
Linezolid |
|
|
|
|
|
|
Clofazimine |
|
|
|
|
|
|
Delamanid |
|
|
|
|
|
|
Pretomamid |
|
|
|
|
|
|
Molecular Results Worksheet: Isolate Method
Drug |
Mutation Detected |
Mutation Not Detected |
No Result |
Not Done |
Rifamycins (Rifampin, Rifabutin, Rifapentine) |
|
|
|
|
Isoniazid |
|
|
|
|
Ethambutol |
|
|
|
|
Pyrazinamide |
|
|
|
|
Streptomycin |
|
|
|
|
Ofloxacin |
|
|
|
|
Ciprofloxacin |
|
|
|
|
Moxifloxacin |
|
|
|
|
Levofloxacin |
|
|
|
|
Amikacin |
|
|
|
|
Kanamycin |
|
|
|
|
Capreomycin |
|
|
|
|
Ethionamide |
|
|
|
|
Cycloserine |
|
|
|
|
Para-aminosalicylic Acid |
|
|
|
|
Bedaquiline |
|
|
|
|
Linezolid |
|
|
|
|
Clofazimine |
|
|
|
|
Delamanid |
|
|
|
|
Pretomanid |
|
|
|
|
File Type | application/vnd.openxmlformats-officedocument.wordprocessingml.document |
Author | Yakrus, Mitchell (CDC/OID/NCHHSTP) |
File Modified | 0000-00-00 |
File Created | 2023-08-27 |